Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2024-10 · 10 (4)
DOI: 10.1002/trc2.70013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 14.12.2024. Verfasst von Clifford R Jack und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Mayo Clinic Rochester Minnesota USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and clinical care. In this article, we outline a summary of the newly proposed “Revised Criteria for Diagnosis and Staging of AD: AA Workgroup” and provide highlights from the AARR meeting in fall 2023. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the Revised Criteria for Diagnosis and Staging of AD: AA Workgroup , and gather industry perspectives and feedback on these revised criteria before its publication. The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care. Improving the availability and accuracy of biomarkers, especially blood‐based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology Mayo Clinic Rochester Minnesota USA.
- Novartis Pharma AG Basel Switzerland.
- Eli Lilly and Company Boston Massachusetts USA.
- Eli Lilly and Company Indianapolis Indiana USA.
- Athira Pharma Inc. Bothell Washington USA.
- Acumen Pharmaceuticals Zionsville Indiana USA.
Zitieren
APA
Jack, C. R., Graf, A., Burnham, S. C., Doty, E. G., Moebius, H. J., Montenigro, P., Siemers, E., Sink, K. M., Shaw, L. M., Hansen, C. T., Wildsmith, K. R., Mahinrad, S., Carrillo, M. C., & Weber, C. J. (2024). Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10(4). https://doi.org/10.1002/trc2.70013
Vancouver
Jack CR, Graf A, Burnham SC, Doty EG, Moebius HJ, Montenigro P, et al. Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2024;10(4). doi:10.1002/trc2.70013
BibTeX
@article{Jack2024,
author = {Jack, Clifford R and Graf, Ana and Burnham, Samantha C and Doty, Erin G and Moebius, Hans J and Montenigro, Philip and Siemers, Eric and Sink, Kaycee M and Shaw, Leslie M and Hansen, Charlotte Thim and Wildsmith, Kristin R and Mahinrad, Simin and Carrillo, Maria C and Weber, Christopher J},
title = {Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice},
journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
year = {2024},
volume = {10},
number = {4},
doi = {10.1002/trc2.70013}
}
EUVIMED